Register for a Clinical Trial

Protocol IDN-6556-17
Title A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Area Liver
Indication Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Treatment Emricasan is a small molecule irreversible caspase inhibitor. It is hypothesized that inhibition of caspases may have significant therapeutic benefit for the treatment of liver fibrosis, independent of the underlying disease state
Requirement Subject population consists of male or female subjects 18 years of age with a diagnosis of Cirrhosis due to NASH with exclusion of other causes of cirrhosis. Study duration is 54 weeks with subjects randomized in a 1:1:1 fashion.
Your First Name:
Your Last Name:
Phone Number:
ZIP Code:
E-mail Address: